About Index Trending news
Analyze
Pricing
PULMOCIDE LIMITED

PULMOCIDE LIMITED

Work at PULMOCIDE LIMITED? Add yourself to this profile

PULMOCIDE LIMITED

Pulmocide is focused on the development of inhaled medicines for the treatmentof viral and fungal infections of the respiratory tract.

Elsewhere

Contributors to this profile

Alexa global traffic share

20 Mar 2017
$30,000,000
Venture capital (Series B)
SV Life Sciences, F-Prime Capital Partners, Johnson & Johnson, +2

British biotech Pulmocide raises £24m in bid to find treatment for deadly lung diseases

The Telegraph
+1
26 Nov 2013
$27,541,217
Venture capital (Series A)